These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 8239565)
41. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease. Hauser RA; Holford NH Mov Disord; 2002 Sep; 17(5):961-8. PubMed ID: 12360545 [TBL] [Abstract][Full Text] [Related]
42. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222 [TBL] [Abstract][Full Text] [Related]
43. Activation by selegiline (Eldepryle) of REM sleep behavior disorder in parkinsonism. Louden MB; Morehead MA; Schmidt HS W V Med J; 1995; 91(3):101. PubMed ID: 7747490 [TBL] [Abstract][Full Text] [Related]
44. Treatment of Parkinson's disease: levodopa as the first choice. Katzenschlager R; Lees AJ J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059 [TBL] [Abstract][Full Text] [Related]
45. Sleep patterns in Parkinson's disease patients with visual hallucinations. Barnes J; Connelly V; Wiggs L; Boubert L; Maravic K Int J Neurosci; 2010 Aug; 120(8):564-9. PubMed ID: 20615061 [TBL] [Abstract][Full Text] [Related]
46. Rapid eye movement sleep behavior disorder and subtypes of Parkinson's disease. Romenets SR; Gagnon JF; Latreille V; Panniset M; Chouinard S; Montplaisir J; Postuma RB Mov Disord; 2012 Jul; 27(8):996-1003. PubMed ID: 22733427 [TBL] [Abstract][Full Text] [Related]
47. Comparison of the clinical features of rapid eye movement sleep behavior disorder in patients with Parkinson's disease and multiple system atrophy. Nomura T; Inoue Y; Högl B; Uemura Y; Yasui K; Sasai T; Namba K; Nakashima K Psychiatry Clin Neurosci; 2011 Apr; 65(3):264-71. PubMed ID: 21507133 [TBL] [Abstract][Full Text] [Related]
48. Testosterone not associated with violent dreams or REM sleep behavior disorder in men with Parkinson's. Chou KL; Moro-De-Casillas ML; Amick MM; Borek LL; Friedman JH Mov Disord; 2007 Feb; 22(3):411-4. PubMed ID: 17230453 [TBL] [Abstract][Full Text] [Related]
49. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease. Nausieda PA; Pfeiffer RF; Tagliati M; Kastenholz KV; DeRoche C; Slevin JT Clin Ther; 2005 Jan; 27(1):58-63. PubMed ID: 15763606 [TBL] [Abstract][Full Text] [Related]
50. Age, drugs, or disease: what alters the macrostructure of sleep in Parkinson's disease? Sixel-Döring F; Trautmann E; Mollenhauer B; Trenkwalder C Sleep Med; 2012 Oct; 13(9):1178-83. PubMed ID: 22841842 [TBL] [Abstract][Full Text] [Related]
51. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Burn D; Emre M; McKeith I; De Deyn PP; Aarsland D; Hsu C; Lane R Mov Disord; 2006 Nov; 21(11):1899-907. PubMed ID: 16960863 [TBL] [Abstract][Full Text] [Related]
52. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment]. Jost WH; Klasser M; Reichmann H Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504 [TBL] [Abstract][Full Text] [Related]
54. Periodic leg movements and REM sleep without atonia in Parkinson's disease with camptocormia. Lavault S; Bloch F; Houeto JL; Konofal E; Welter ML; Agid Y; Arnulf I Mov Disord; 2009 Dec; 24(16):2419-23. PubMed ID: 19891002 [TBL] [Abstract][Full Text] [Related]
55. Evaluation of sleep and driving performance in six patients with Parkinson's disease reporting sudden onset of sleep under dopaminergic medication: a pilot study. Möller JC; Stiasny K; Hargutt V; Cassel W; Tietze H; Peter JH; Krüger HP; Oertel WH Mov Disord; 2002 May; 17(3):474-81. PubMed ID: 12112193 [TBL] [Abstract][Full Text] [Related]
56. A six-month study of pergolide and levodopa in de novo Parkinson's disease patients. Kulisevsky J; López-Villegas D; García-Sánchez C; Barbanoj M; Gironell A; Pascual-Sedano B Clin Neuropharmacol; 1998; 21(6):358-62. PubMed ID: 9844794 [TBL] [Abstract][Full Text] [Related]
57. Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Diederich NJ; Moore CG; Leurgans SE; Chmura TA; Goetz CG Arch Neurol; 2003 Apr; 60(4):529-33. PubMed ID: 12707066 [TBL] [Abstract][Full Text] [Related]
58. Frontal dysfunction contributes to the genesis of hallucinations in non-demented Parkinsonian patients. Grossi D; Trojano L; Pellecchia MT; Amboni M; Fragassi NA; Barone P Int J Geriatr Psychiatry; 2005 Jul; 20(7):668-73. PubMed ID: 16021658 [TBL] [Abstract][Full Text] [Related]
59. Clinical vignettes in Parkinson's disease: a collection of unusual medication-induced hallucinations, delusions, and compulsive behaviours. Friedman JH; Agarwal P; Alcalay R; Black KJ; Chou KL; Cote L; Dayalu P; Frank S; Hartlein J; Hauser RA; Lang AE; Marsh L; Marshall F; Moskowitz C; Ravina B; Riley D; Sanchez-Ramos J; Simon DK; Simuni T; Sutton J; Tuite P; Weintraub D; Zesiewicz T Int J Neurosci; 2011 Aug; 121(8):472-6. PubMed ID: 21663381 [TBL] [Abstract][Full Text] [Related]
60. [Clinical characteristics in Parkinson's disease patients with cognitive impairment and effects of cognitive impairment on sleep]. Gong Y; Xiong KP; Mao CJ; Huang JY; Hu WD; Han F; Chen R; Liu CF Zhonghua Yi Xue Za Zhi; 2013 Sep; 93(33):2637-41. PubMed ID: 24360043 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]